Cases & Deals

  • Home
  • Practices
  • AbbVie collaborates to advance novel bispecific antibody for advanced solid tumors

Share

AbbVie collaborates to advance novel bispecific antibody for advanced solid tumors

January 2026

Client(s) AbbVie Inc.

Jones Day advised AbbVie Inc. on an exclusive licensing transaction with RemeGen Co., Ltd. ("RemeGen") relating to a PD-1/VEGF-targeted bispecific antibody, under which RemeGen may receive up to $4.95 billion in milestone payments, plus tiered royalties outside Greater China.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.